Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE Mice Fed High-Fat Diet

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2022 Sep 23

PMID 36148321

Authors

Mengqi Yang

Huachen Jiao

Yan Li

Lei Zhang

Juan Zhang

Xia Zhong

Yitao Xue

Affiliations

Soon will be listed here.

Abstract

Background: Atherosclerosis (AS) is the leading cause of cardiovascular diseases, such as myocardial infarction and stroke. Guanmaitong granule (GMTG) is a TCM (Traditional Chinese medicine) prescribed to treat AS. However, its mechanism remains unclear.

Methods: We obtained reliable ingredients and targets of GMTG using the HERB database. AS-related targets were obtained from HERB and GeneCards databases. The target database was constructed by intersecting the ingredients of GMTG with the AS-related targets. STRING and Cytoscape were used to create protein-protein interaction (PPI) network and screen core targets. GO enrichment analysis and KEGG pathway analyses were performed using R. Finally, the ApoE mice AS model was induced by a high-fat diet (HFD) for in vivo validation of core pathways and targets.

Results: A total of 124 ingredients and 418 potential targets of GMTG for treating AS were obtained. Numerous ingredients and targets were related to , and . Most core targets and pathways were involved in the inflammatory immune response. GMTG could decrease serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and oxidized low-density lipoprotein level and increase the serum high-density lipoprotein-cholesterol level. Furthermore, GMTG reduced the plaque burden and promoted plaque remodeling by reducing plaque area, lipid deposition, foam cell content, and collagen fiber content in the plaque in the aortic root of ApoE mice. GMTG inhibited systemic and plaque inflammatory immune response and increased plaque stability by inhibiting the excessive release of the TLR4/MyD88/NF-κB pathway-induced inflammatory cytokines, tumor necrosis factor, interleukin-6, and interleukin-1 beta.

Conclusion: , and are the main ingredients of GMTG for treating AS. Further, GMTG could regulate the level of serum lipids and inhibit inflammatory immune response, which resulted in anti-AS effects such as plaque stabilization, reduction of plaque burden, and plaque remodeling. GMTG is a promising multi-target treatment for AS.

Citing Articles

Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.

Dai J, Qiu L, Lu Y, Li M Front Endocrinol (Lausanne). 2024; 15:1366285.

PMID: 39403576 PMC: 11471557. DOI: 10.3389/fendo.2024.1366285.

References

Kastelein J, Akdim F, Stroes E, Zwinderman A, Bots M, Stalenhoef A . Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14):1431-43. DOI: 10.1056/NEJMoa0800742. View

Tabas I, Garcia-Cardena G, Owens G . Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015; 209(1):13-22. PMC: 4395483. DOI: 10.1083/jcb.201412052. View

Ahmadsei M, Lievens D, Weber C, von Hundelshausen P, Gerdes N . Immune-mediated and lipid-mediated platelet function in atherosclerosis. Curr Opin Lipidol. 2015; 26(5):438-48. DOI: 10.1097/MOL.0000000000000212. View

Liu Y, Yu H, Zhang Y, Zhao Y . TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med Hypotheses. 2007; 70(2):314-6. DOI: 10.1016/j.mehy.2007.05.030. View

Chen T, Luo W, Wu G, Wu L, Huang S, Li J . A novel MyD88 inhibitor LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. Toxicol Appl Pharmacol. 2019; 370:44-55. DOI: 10.1016/j.taap.2019.03.012. View

Layland J, Carrick D, Lee M, Oldroyd K, Berry C . Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv. 2014; 7(6):581-91. DOI: 10.1016/j.jcin.2014.02.009. View

Tu Y, Lian T, Yen J, Chen Z, Wu M . Antiatherogenic effects of kaempferol and rhamnocitrin. J Agric Food Chem. 2007; 55(24):9969-76. DOI: 10.1021/jf0717788. View

Park E, Lee A, Park S, Kim J, Cho M . Multiple pathways are involved in palmitic acid-induced toxicity. Food Chem Toxicol. 2014; 67:26-34. DOI: 10.1016/j.fct.2014.01.027. View

Zhang X, Xue C, Xu Q, Zhang Y, Li H, Li F . Caprylic acid suppresses inflammation via TLR4/NF-κB signaling and improves atherosclerosis in ApoE-deficient mice. Nutr Metab (Lond). 2019; 16:40. PMC: 6555760. DOI: 10.1186/s12986-019-0359-2. View

10.

Fukumoto Y, Libby P, Rabkin E, Hill C, Enomoto M, Hirouchi Y . Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001; 103(7):993-9. DOI: 10.1161/01.cir.103.7.993. View

11.

Zhu L, Gong X, Gong J, Xuan Y, Fu T, Ni S . Notoginsenoside R1 upregulates miR-221-3p expression to alleviate ox-LDL-induced apoptosis, inflammation, and oxidative stress by inhibiting the TLR4/NF-κB pathway in HUVECs. Braz J Med Biol Res. 2020; 53(6):e9346. PMC: 7233198. DOI: 10.1590/1414-431x20209346. View

12.

Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-64. DOI: 10.1001/jama.2011.860. View

13.

Chapman M, Ginsberg H, Amarenco P, Andreotti F, Boren J, Catapano A . Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11):1345-61. PMC: 3105250. DOI: 10.1093/eurheartj/ehr112. View

14.

Fang S, Dong L, Liu L, Guo J, Zhao L, Zhang J . HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 2020; 49(D1):D1197-D1206. PMC: 7779036. DOI: 10.1093/nar/gkaa1063. View

15.

Do R, Willer C, Schmidt E, Sengupta S, Gao C, Peloso G . Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45(11):1345-52. PMC: 3904346. DOI: 10.1038/ng.2795. View

16.

Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N . Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 117(4):e25-146. DOI: 10.1161/CIRCULATIONAHA.107.187998. View

17.

Sampson U, Fazio S, Linton M . Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2011; 14(1):1-10. PMC: 3697085. DOI: 10.1007/s11883-011-0219-7. View

18.

Libby P . Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001; 104(3):365-72. DOI: 10.1161/01.cir.104.3.365. View

19.

Newman C, Preiss D, Tobert J, Jacobson T, Page 2nd R, Goldstein L . Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2018; 39(2):e38-e81. DOI: 10.1161/ATV.0000000000000073. View

20.

Chistiakov D, Melnichenko A, Grechko A, Myasoedova V, Orekhov A . Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018; 104(2):114-124. DOI: 10.1016/j.yexmp.2018.01.008. View